Compare Cassava Sciences Inc (FLNA) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PepsiCo, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while PepsiCo, Inc. trades at $136.88 (market cap $184.81B). The key difference: PepsiCo, Inc. is far larger — about 3477.8× Cassava Sciences Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PEP | |
|---|---|---|
Market Cap | $53.14M | $184.81B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $170.44 |
52-Week Low | $1.09 | $135.35 |
Enterprise Value | -$33.43M | $227.30B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
PepsiCo (PEP) trades at $135.45, down 2.2% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The stock faces pressure from consumer resistance to snack price increases, with recent news highlighting price cuts of up to 15% on products like Doritos. Fundamentally, PEP maintains strong profitability with a 10.78% net margin and 51.59% ROE, though 2025 revenue growth slowed to 2.2% year-over-year. Analyst consensus remains positive with a $159.27 price target, representing 17.6% upside potential from current levels.
The investment case balances strong cash flow generation and dividend reliability against volume sensitivity to pricing actions. Near-term performance hinges on Q1 2026 results due next week, where investors will scrutinize North American recovery trends. While valuation appears reasonable at 17.75x P/E, execution risks around price optimization and competitive pressures warrant monitoring. The current technical weakness may present entry opportunities for long-term investors seeking stable consumer staples exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
